Abstract: Intrahepatic cholangiocarcinoma (ICC) is a relatively rare type of primary liver cancer, with an increasing incidence in recent years. Due to its insidious onset and atypical clinical symptoms, most patients are diagnosed at an advanced stage of the disease, making timely diagnosis and treatment crucial. The standard treatment for early-stage ICC patients is radical … Read more
Updates on the first human study data from Phase I/II show that B7-H3 targeted ADCs continue to demonstrate therapeutic potential. In recent years, antibody-drug conjugates (ADCs) have emerged as a new class of drugs that bring new “hope” to the treatment of advanced cancer patients due to their unique mechanisms of action. The B7 family … Read more
If a few years ago, presenting a simple PowerPoint on the ADC field could impress without the need for future visions, cutting-edge technologies, or a vibrant pipeline forest, today, the ADC field requires substantial content to make an impact. This shift is attributed to advancements in industry technology and rising awareness. Data shows that from … Read more
Source: Wang Xin, Rao Benqiang. High-Dose Vitamin C Precision Therapy for Tumors [J/CD]. Journal of Tumor Metabolism and Nutrition, 2023, 10(3): 307-312. Article link: http://182.92.200.144/CN/abstract/abstract1016.shtml Expert Introduction Rao Benqiang, Deputy Director of the Second Department of Gastrointestinal Surgery at Beijing Shijitan Hospital, Capital Medical University, Deputy Director of the National Market Supervision Key Laboratory (Tumor … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogenic structures without harming normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After … Read more
As of now, the toxicity and prevention measures of ADC in solid tumors are known as follows: ① The indications for ADCs are rapidly expanding, gradually shifting from late-stage to early-stage, and from single therapy to combination strategies. ② The toxicity characteristics of most ADCs are similar to the cytotoxicity of their payloads. ③ Certain … Read more
▎This article is contributed by Ying’en Biotech (slightly edited) Since the first antibody-drug conjugate (ADC) was approved for the treatment of acute myeloid leukemia in 2000, after more than twenty years of exploration and development, 14 ADC drugs have been successfully approved for clinical treatment of tumors. In August 2022, the FDA announced the accelerated … Read more
Since the end of 2019 and the beginning of 2020, I have been looking at ADCs, and I have discussed with many experts in the field, leading to many misunderstandings, and my understanding has been continuously refreshed. Many articles about ADCs exist, but many of them contain misunderstandings. Now, there are more successful and failed … Read more
Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more